Late Breaking Clinical Trials Presented at HFSA 13th Annual Scientif...(toring in HF patients: Results of the FA...),Health

Date:9/14/2009

toring in HF patients: Results of the FAST trial. This trial focused on comparing the relative sensitivity and unexplained detection rate of changes in daily weights vs. intrathoracic impedance changes. The trial concluded that the sensitivity and unexplained detection rate of an intrathoracic fluid index were superior to those for acute weight changes in HF patients with implantable devices. Intrathoracic impedance monitoring represents a positive addition to our armamentarium for managing HF and should be considered for routine use in patients with implanted devices with this feature in addition to daily weight monitoring.

Effects of rolofylline, a selective adenosine A1 receptor antagonist, in patients hospitalized for acute decompensated heart failure and renal impairment: Findings from the PROTECT study. This trial was designed to test the hypothesis that the selective A1 adenosine receptor antagonist rolofylline would safely improve HF signs and symptoms, reduce the risk of worsening renal function and reduce morbidity and mortality when used with IV loop diuretics in subjects with ADHF, volume overload and renal impairment. Surprisingly and disappointedly, rolofylline was not associated with an improvement in the primary endpoint or the two secondary endpoints including renal function. This trial, the largest to date in ADHF, will require further analysis to help investigators develop new strategies for the important but complicated condition of ADHF.

"Each year we discover new and innovative treatments for patients living with heart failure," said Dr. Douglas Mann, HFSA President. "It is important for the medical community to continue to utilize science and clinical medicine to improve care that we provide to patients with heart failure."

For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7183 or visit '/>"/>

SOURCE The Heart Failure Society of America Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
2. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
3. UNT Health Science Centers Groundbreaking Research Applied to Protecting Brain After Traumatic Injury
4. Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
5. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
6. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
7. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
8. Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study
9. Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting
10. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
11. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting